Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

XMP-629 enters phase II for acne

Jan. 26, 2004

Enrollment completed in phase I Psoraxine trial

Jan. 26, 2004

Protective effects against UV irradiation reported for topical lycopene

Jan. 21, 2004

Galderma describes two series of RAR antagonists for dermatological disorders

Jan. 20, 2004

Initial dosing completed in phase I trial of MRE-0094

Jan. 16, 2004

Phase II trial confirms icatibant utility in hereditary angioedema

Jan. 15, 2004

End of patient enrollment announced for two clinical trials with Velac(R) Gel

Jan. 13, 2004

Atrisone completes pivotal phase III acne studies

Jan. 8, 2004

Topical tacrolimus reported effective for oral lichen planus and facial psoriasis

Dec. 30, 2003

PMA filing commences for OrCel for venous leg ulcers

Dec. 30, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...